This Small-Cap Diagnostics Company Just Joined the Coronavirus Battle

Cincinnati-based Meridian Bioscience (NASDAQ: VIVO) would seem to be an unlikely player in the global coronavirus fight. This week, however, the company announced that one of its reagents is being used in the development of molecular diagnostics for that virus.

Because the reagent is very stable, it can be freeze-dried, and thus is readily available for a patient sample to be run quickly for diagnosis -- important in a situation where time is crucial to help contain the outbreak.

According to the company's product marketing manager: "Over the last few days we have seen significant demand for our Lyo-Ready One-Step RT-qPCR Mix. This ready-to-use ... mix is designed to improve the accuracy of assays, increase operational efficiencies, and reduce their overall costs, making screening fast and affordable."

Source Fool.com